ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE

Abstract SL-701 is a novel immunotherapy comprised of synthetic peptides designed to elicit an anti-tumor immune response against GBM targets: interleukin-13 receptor alpha-2, EphrinA2 and Survivin. Updated Phase 2 data are reported. Patients with previously treated GBM, bevacizumab (bev)-naive, HLA...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2018-11, Vol.20 (suppl_6), p.vi2-vi2
Hauptverfasser:	Peereboom, David, Nabors, L Burt, Kumthekar, Priya, Badruddoja, Michael, Fink, Karen, Lieberman, Frank, Phuphanich, Surasak, Dunbar, Erin, Walbert, Tobias, Schiff, David, Tran, David, Ashby, Lynn, Butowski, Nicholas, Iwamoto, Fabio, Lindsay, Ross, Bullington, John, Schulder, Michael, Sherman, Jonathan, Brooks, Chris, Reardon, David
Format:	Artikel
Sprache:	eng
Schlagworte:	Abstracts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!